Home Work Product development

GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world. Since its inception, GALVmed has worked on 13 priority diseases that have been identified as imposing severe constraints on small-scale agriculture in the developing world. In addition to these diseases GALVmed will continue to consider the inclusion of additional diseases based on evidence of need and the potential for benefitting smallholders. Our intention is to work on the development of 25 products and product related technologies (processes or platforms that will increase access to products). These will comprise an approximate 50:50 mix of new and enhanced existing products and technologies. The products will cover 13 of GALVmed’s priority diseases, plus possibly new diseases in future.

GALVmed maintains a small R&D team that works through an extensive network of partners comprising Contract Research Organisations (CROs), commercial and academic laboratories, research institutes and quasi-governmental organisations. A broad range of R&D activities take place through these partners and components of this work include:

  • Drug discovery
  • Formulation science
  • Antigen identification
  • Biological process enhancements
  • Clinical studies for product registration
  • Epidemiological investigation

Within the full range of activities above, the broad focus of GALVmed’s R&D work is on the translation of outcomes from basic research through to product development, registration, manufacturing and commercialisation. The objective is always to hand the product over, under GALVmed’s principle of Global Access, to a market-orientated partner. This point of hand-over will vary from product to product and depend on a range of circumstances.

Within these diseases, the principal focus is on vaccines, in recognition of their immense value in the small-scale context. In addition to vaccines, the product portfolio includes therapeutic and diagnostic candidates for those diseases where these products can have a significant beneficial impact. The species covered continue to reflect the principle livestock of smallholders: cattle, sheep, goats, swine and poultry.